Skip to main content

Immunologist Daniel Mucida promoted to professor

A pioneer in the field of mucosal immunology, Mucida is unlocking the secrets of the digestive system and answering fundamental questions about the origins of human disease.

Mary Jeanne Kreek, pioneer in studies of addiction, has died

Kreek conducted landmark studies that led to the establishment of methadone as a treatment for heroin addiction. Her work not only yielded new treatments for addiction disorders, but also influenced societal attitudes toward them. She was 84.

Paula Volent is named chief investment officer

The university has named its next vice president and chief investment officer. Volent, who for decades oversaw investments at Bowdoin College, will assume stewardship of Rockefeller's endowment in August.

>

How one patient’s rare mutation helped solve a mycobacterial mystery

The discovery may explain why some patients suffer more severe reactions than others—putting us one step closer to understanding how our DNA influences our susceptibility to a wide range of infectious diseases.

Financial crashes, pandemics, Texas snow: How math could predict "black swan" events

Statistical modeling may one day help scientists anticipate and manage a wide range of extreme occurrences, according to a new study.

An old antibiotic may combat drug-resistant tuberculosis

Drug-resistant strains of tuberculosis bacteria affect half a million people a year. A compound first discovered in the 1980s may be able to help.

Why male mosquitoes leave humans alone

Unlike their female counterparts, male mosquitoes have no desire to bite us. But the hardware for host-seeking is hidden in the male mosquito brain, locked behind a simple genetic switch. 

This fish is about to flip 

An elaborate set of zebrafish experiments is shining light on one of neuroscience’s greatest enigmas: How brains make decisions. By tracking neural activity, scientists can now predict a fish’s next move before it happens.

Rockefeller grants commercial license for the development of monoclonal antibodies for treatment of COVID-19

The treatment, a combination of two antibodies, has been shown highly capable of neutralizing SARS-CoV-2 in preclinical studies. Researchers hope it will give countries around the world, including developing countries, a way to control the rampant disease.

COVID-19 vaccines may need regular updates for emerging variants

Lab experiments suggest that the new strains reported in Britain, South Africa, and Brazil may blunt the potency of the Pfizer and Moderna COVID-19 vaccines. This could mean that the vaccines will need updates as the virus mutates.